


SDU-071

Cat. No.:	HY-162352
Molecular Formula:	C ₂₈ H ₂₅ N ₃ O ₂
Molecular Weight:	435.52
Target:	Epigenetic Reader Domain; Apoptosis
Pathway:	Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SDU-071 is a potent and orally active inhibitor of BRD4-p53 inhibitor. SDU-071 inhibits MDA-MB-231 cells proliferation with an IC ₅₀ of 10.5 μM. SDU-071 induces cell cycle arrest and apoptosis ^[1] .									
In Vitro	<p>SDU-071 (10 μM, 24 h) induces cell-cycle arrest and apoptosis in MDA-MB-231 cells^[1]. SDU-071 (10 μM, 72 h) inhibits cell proliferation, migration, and invasion in MDA-MB-231 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MDA-MB-231cells</td> </tr> <tr> <td>Concentration:</td> <td>2.5, 5, and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Altered cell cycle progression in the G1, S, and G2/M phases. Induced apoptosis in MDA-MB-231 cells.</td> </tr> </table>		Cell Line:	MDA-MB-231cells	Concentration:	2.5, 5, and 10 μM	Incubation Time:	24 hours	Result:	Altered cell cycle progression in the G1, S, and G2/M phases. Induced apoptosis in MDA-MB-231 cells.
Cell Line:	MDA-MB-231cells									
Concentration:	2.5, 5, and 10 μM									
Incubation Time:	24 hours									
Result:	Altered cell cycle progression in the G1, S, and G2/M phases. Induced apoptosis in MDA-MB-231 cells.									
In Vivo	<p>SDU-071 (250 mg/kg for i.g; once daily for 21 days) inhibits tumor growth in a MDA-MB-231 orthotopic mouse xenograft mammary tumor model^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 and 250 mg/kg; Once daily for 21 days</td> </tr> <tr> <td>Administration:</td> <td>Gavage administration (i.g.)</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited tumor growth with 49.1% inhibition. Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein.</td> </tr> </table>		Animal Model:	DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model ^[1]	Dosage:	50 and 250 mg/kg; Once daily for 21 days	Administration:	Gavage administration (i.g.)	Result:	Significantly inhibited tumor growth with 49.1% inhibition. Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein.
Animal Model:	DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model ^[1]									
Dosage:	50 and 250 mg/kg; Once daily for 21 days									
Administration:	Gavage administration (i.g.)									
Result:	Significantly inhibited tumor growth with 49.1% inhibition. Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein.									

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA